Generic selectors
Exact matches only
Search in title
Search in content

FOLLOW US: 

September 19, 2019

Fournier’s Gangrene Risk from Invokana Potentially Confirmed by New Study

A new study may confirm the risk of developing Fournier’s gangrene after taking diabetes drugs like Invokana. Fournier’s gangrene, a potentially life-threatening, flesh-eating genital infection, has allegedly caused the suffering of Invokana users according to lawsuits across the country.

JAMA Internal Medicine, a medical journal, recently published a research letter earlier this month that found an increased risk of Fournier’s gangrene among sodium-glucose contrasoperter-2 (SGLT-2) inhibitors. SGLT-2 inhibitors are a new class of diabetes drugs that help remove glucose from the body, including drugs like Invokana, Farxiga, and Jardiance. However, since Invokana, the first SGLT-2 inhibitor, was released to the market in 2013, researchers have been discovering numerous adverse health risks caused by Invokana and similar SGLT-2 inhibitors. In fact, the findings of this 2019 study confirm results first released by FDA researchers in 2018 that raised initial concerns about patients’ risk of developing Fournier’s gangrene from taking SGLT-2 inhibitors. JAMA analyzed the FDA’s 2018 findings of increased Fournier’s gangrene risk and published their evaluation in October 2018.

“Infections developed in all 12 patients within several months of starting an SGLT-2 inhibitor,” JAMA stated in their report. “All were hospitalized and required surgery that in some was disfiguring or resulted in complications. One patient died.”

JAMA indicated that there were likely far more cases of Fournier’s gangrene caused by Invokana and other SGLT-2 inhibitors than the FDA initially predicted.

However, though the risk of Fournier’s gangrene is present, the researchers of this most recent study indicate that the risk of infection does not outweigh the benefits of taking SGLT-2 inhibitors.

Invokana Lawsuits


After FDA researchers found an increased risk of patients developing Fournier’s gangrene after taking Invokana and similar drugs, the FDA ordered for new warning labels to be added to all SGLT-2 inhibitors, such as Invokana, Synjardy, Steglujan, etc. Previously, warning labels for serious side effects such as diabetic ketoacidosis, kidney failure, and amputation (specifically for Invokana) were added to SGLT-2 inhibitors’ packaging and information labels. When these drugs were first approved by the FDA, they did not carry warnings for any of these adverse side effects. As the first SGLT-2 inhibitor released to the market, Invokana manufacturers and sellers now face numerous lawsuits from injured Invokana users across the country. Invokana patients allege that Invokana manufacturers like Johnson & Johnson and Janssen were negligent in warning patients about the severe heath risks of taking Invokana, contributing to the injuries of patients across the country.

Recent Posts

$2 Billion Roundup Settlement Reached Over Glyphosate Cancer Claims

Roundup Victims Could Receive Up To $200,000 On February 3, Bayer AG reached a $2 billion deal to settle future legal claims that their Roundup weedkiller causes cancer. The German company announced the settlement will cover future claims brought by consumers who were exposed to Roundup and later diagnosed with non-Hodgkin’s lymphoma. For nearly three […]

Read More
5 Questions to Ask Before Hiring an Attorney

"What Questions Should I Ask Before Hiring an Attorney?" Hiring an attorney is a big decision. There’s no doubt about that! When you hire an attorney to handle your personal injury case, you’re not just employing someone to sort through the paperwork and explain the “legalese.” You’re choosing someone to partner with, someone who will […]

Read More

Contact Us Today for your free, in-depth case evaluation

We're on Your Side
We're available 24/7
no fees unless you win

Free in-depth 
no obligation case evaluation

envelopeprinterphone-handsetmap-markerarrow-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram